LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.91 0.39

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.69

Max

13.59

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+146.3% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-241M 1.1B
Vorige openingsprijs	12.52
Vorige sluitingsprijs	12.91

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mei 2026, 21:33 UTC

Winsten

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mei 2026, 21:00 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mei 2026, 20:18 UTC

Winsten

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mei 2026, 23:49 UTC

Marktinformatie

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mei 2026, 23:39 UTC

Marktinformatie

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mei 2026, 23:34 UTC

Marktinformatie

Global Equities Roundup: Market Talk

27 mei 2026, 23:08 UTC

Marktinformatie

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mei 2026, 22:21 UTC

Marktinformatie

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mei 2026, 21:29 UTC

Populaire aandelen

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mei 2026, 21:08 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mei 2026, 21:02 UTC

Winsten

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mei 2026, 20:59 UTC

Acquisities, Fusies, Overnames

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mei 2026, 20:55 UTC

Winsten

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

27 mei 2026, 20:48 UTC

Winsten

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mei 2026, 20:45 UTC

Winsten

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mei 2026, 20:34 UTC

Acquisities, Fusies, Overnames

Webster Financial Stockholders Approve Sale to Banco Santander

27 mei 2026, 20:32 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mei 2026, 20:32 UTC

Acquisities, Fusies, Overnames

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mei 2026, 20:30 UTC

Winsten

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mei 2026, 20:30 UTC

Acquisities, Fusies, Overnames

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mei 2026, 20:22 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:16 UTC

Winsten

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mei 2026, 20:13 UTC

Winsten

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mei 2026, 20:13 UTC

Winsten

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mei 2026, 20:12 UTC

Winsten

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

146.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 146.3%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.